| Autor: |
Coleman, Patrick J., Nissen, Alexander P., Kim, Daniel E., Ainsworth, Craig R., McCurdy, Michael T., Mazzeffi, Michael A., Chow, Jonathan H. |
| Zdroj: |
Seminars in Cardiothoracic & Vascular Anesthesia; Sep2020, Vol. 24 Issue 3, p266-272, 7p |
| Abstrakt: |
This case describes the first reported use of human-derived synthetic angiotensin II (Ang-2) in a patient with decompensated cirrhosis and septic shock. The patient presented in vasodilatory shock from Enterobacter cloacae bacteremia with a Sequential Organ Failure Assessment Score of 14 and a Model for End-Stage Liver Disease score of 36. This case is significant because liver failure was an exclusion criterion in the Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial, but the liver produces angiotensinogen, which is key precursor to Ang-2 in the renin-angiotensin-aldosterone system. Resuscitation with Ang-2 is a potentially beneficial medication when conventional vasopressors have failed to control mean arterial pressure in this population. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
